In this discussion, researchers Jun Zhang, Lanlan Zhou, Shuai Zhao, and Wafik S. El-Deiry delve into innovative approaches for tackling refractory metastatic gastrointestinal cancers. They unveil exciting findings on the synergistic effects of the FDA-approved drugs TAS102 and regorafenib. Their research suggests this combination could improve survival rates and combat cancer stemness. With promising preclinical results, they emphasize the need for further clinical studies to validate these advances in cancer treatment.

Researchers Wafik S. El-Deiry and Shengliang Zhang discuss how the SARS-CoV-2 spike protein disrupts the p53 tumor suppressor pathway in cancer cells, potentially compromising its functions and increasing cancer cell viability. They highlight the need for further research to understand the implications of SARS-CoV-2 infection on cancer treatment outcomes.